Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study for its SHP2 inhibitor BBP-398 in Chinese patients with advanced solid tumors. This marks a significant step forward in the development of BBP-398, which targets the SHP2 protein-tyrosine phosphatase. SHP2 links growth factor, cytokine, and integrin signaling with the downstream RAS/MAPK pathway, regulating cellular proliferation and survival. Overactivity of SHP2 is a critical contributor to many forms of cancer and can suppress antitumor immunity.
BBP-398 Profile
Data generated to date suggest that BBP-398 has a promising pharmacokinetic profile, which could provide key advantages as a backbone combination therapy. The Phase I study is designed to examine the safety and preliminary anti-tumor activity of BBP-398. This two-part, open-label, dose escalation and dose expansion study will provide valuable insights into the drug’s potential as a treatment for advanced solid tumors.
Partnership and Future Plans
LianBio formed an in-depth partnership with BridgeBio in November 2020, securing development and commercialization rights in China and other Asian markets for both infigratinib and the SHP2 inhibitor BBP-398. LianBio expects to initiate a Phase I clinical trial of BBP-398 in combination with an EGFR inhibitor in Chinese patients with EGFR-mutant non-small cell lung cancer (NSCLC) in the first half of 2023. This strategic move underscores LianBio’s commitment to advancing innovative cancer therapies.-Fineline Info & Tech
